X-ray fluorescence microscopy and X-ray absorption spectroscopy reveal the stability of the plecstatin-1 scaffold in biological model systems: comparison of Ru, Os and Ir analogues
Date
2025
Authors
Lovett, J.H.
Lai, B.P.
Bloomfield, H.O.
Baker, A.T.
Sullivan, M.P.
Hartinger, C.G.
Harris, H.H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Chemical Science, 2025; 16(25):11347-11358
Statement of Responsibility
James H. Lovett, Barry P. Lai, Hugh O. Bloomfield, Ani T. Baker, Matthew P. Sullivan, Christian G. Hartinger and Hugh H. Harris
Conference Name
Abstract
Plecstatin-1 ([RuCl(p-cym)(pca)]Cl; p-cym = p-cymene, pca = (4-fluorophenyl-2-pyridinecarbothioamide)) is an organometallic anticancer compound of the ruthenium "piano-stool"/"half-sandwich" class which displays promising pre-clinical results. Its mode of action is ascribed to targeting plectin in the cytoskeleton to inhibit cancer cell motility. In this research, we report X-ray fluorescence microscopy (XFM) data demonstrating that the cellular distributions of the metals from the Os and Ir analogues of plecstatin-1 are identical to that of Ru in SKOV-3 ovarian cancer cells treated with plecstatin-1. Extended X-ray absorption fine structure (EXAFS) spectroscopy data confirms that both the p-cym, and the ancillary pca ligand, remain coordinated after incubation of plecstatin-1 in cell media (in the presence or absence of foetal bovine serum), or, in whole human blood, with the likely ligand substitution of the chlorido ligand for a thiol when available. The apparent stability of the complex scaffold to challenge from a wide variety of biological ligands can be used to rationalise the similar cell targeting behaviour of the Ru, Os and Ir complexes.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 The Author(s). Published by the Royal Society of Chemistry. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence